Cancer: A bioelectric disease?

Abstract

Cancer progression is driven by coordinated alterations in signalling networks that regulate proliferation, plasticity, metabolism and therapeutic response. Although genetic and epigenetic mechanisms are well characterised, there is an increasing body of evidence that suggests bioelectric signalling constitutes an additional integrative regulatory layer in tumour biology. In diverse experimental systems, malignant cells consistently exhibit depolarised transmembrane potentials (V_m), which correlate with proliferation, stemness, invasion and therapy resistance, suggesting depolarisation as a conserved bioelectric hallmark of malignancy. This shifts the central question from whether cancer can be considered a bioelectric disease to the extent to which bioelectric signalling constitutes a relevant organising dimension of tumour biology.

However, a quantitative, translationally actionable framework for membrane potential in cancer is lacking. Existing studies and reviews have largely focused on individual ion channels, specific tumour contexts, or conceptual aspects of bioelectricity without systematically establishing V_m as a cross-tumour, systems-level state variable.

Here, we summarise approximately 15 years of experimental and translational research to evaluate the extent to which V_m functions as an integrative regulatory dimension of malignancy. Here, we define a state variable as a measurable, dynamically tuneable parameter that integrates multiple regulatory inputs and predicts system-level cellular behaviour.

At the same time, we identify key limitations in the current evidence base, including limited quantitative comparability across tumour types, incomplete mechanistic integration across regulatory layers, insufficient resolution of tumour heterogeneity and a lack of standardisation for clinical translation.

Based on this review, we introduce a quantitative framework and a structured translational roadmap for incorporating bioelectric state control into precision oncology. This establishes membrane potential as not only a supplementary biomarker, but also a functional pharmacodynamic indicator and an actionable control variable for state-guided therapeutic intervention.

Keywords

bioelectric biomarkers / bioelectric signalling / cancer bioelectricity / ion channels in cancer / membrane potential (V_m) / precision oncology / tumour progression and stemness / tumour-treating fields

References

[1] Levin M, Pezzulo G, Finkelstein JM. Endogenous bioelectric signaling networks: exploiting voltage gradients for control of growth and form. Annu Rev Biomed Eng. 2017; 19: 353-387.

[2] Levin M. Bioelectrical approaches to cancer as a problem of the scaling of the cellular self. Prog Biophys Mol Biol. 2021; 165: 102-113.

[3] Yang M, Brackenbury WJ. Membrane potential and cancer progression. Front Physiol. 2013; 4.

[4] Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022; 12: 31-46.

[5] Giammello F, Biella C, Priori EC, et al. Modulating voltage-gated sodium channels to enhance differentiation and sensitize glioblastoma cells to chemotherapy. Cell Commun Signal CCS. 2024; 22: 434.

[6] Lobikin M, Chernet B, Lobo D, Levin M. Resting potential, oncogene-induced tumorigenesis, and metastasis: the bioelectric basis of cancer in vivo. Phys Biol. 2012; 9:065002.

[7] Binggeli R, Weinstein RC. Deficits in elevating membrane potential of rat fibrosarcoma cells after cell contact. Cancer Res. 1985; 45: 235-241.

[8] Marino AA, Iliev IG, Schwalke MA, Gonzalez E, Marler KC, Flanagan CA. Association between cell membrane potential and breast cancer. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 1994; 15: 82-89.

[9] Nilsson Å, Lidén E, Sellström Å. Some observations made by intracellular recordings in a primary astrocyte culture and a glioblastoma ‘138 MG’. Acta Physiol Scand. 1986; 126: 413-417.

[10] Sun D, Gong Y, Kojima H, et al. Increasing cell membrane potential and GABAergic activity inhibits malignant hepatocyte growth. Am J Physiol-Gastrointest Liver Physiol. 2003; 285: G12-9.

[11] Chernet BT, Levin M. Transmembrane voltage potential of somatic cells controls oncogene-mediated tumorigenesis at long-range. Oncotarget. 2014; 5: 3287-3306.

[12] Chernet BT, Levin M. Transmembrane voltage potential is an essential cellular parameter for the detection and control of tumor development in a Xenopus model. Dis Model Mech. 2013;dmm.010835.

[13] Yang M, Brackenbury WJ. Harnessing the membrane potential to combat cancer progression. Bioelectricity. 2022; 4: 75-80.

[14] Soto-Cerrato V, Manuel-Manresa P, Hernando E, et al. Facilitated anion transport induces hyperpolarization of the cell membrane that triggers differentiation and cell death in cancer stem cells. J Am Chem Soc. 2015; 137: 15892-15898.

[15] Payne SL, Levin M, Oudin MJ. Bioelectric control of metastasis in solid tumors. Bioelectricity. 2019; 1: 114-130.

[16] Blackiston DJ, McLaughlin KA, Levin M. Bioelectric controls of cell proliferation: ion channels, membrane voltage and the cell cycle. Cell Cycle. 2009; 8: 3527-3536.

[17] Shrivastava A, Kumar A, Aggarwal LM, et al. Evolution of bioelectric membrane potentials: implications in cancer pathogenesis and therapeutic strategies. J Membr Biol. 2024; 257: 281-305.

[18] Delisi D, Eskandari N, Gentile S. Membrane potential: a new hallmark of cancer. Adv Cancer Res. 2024; 164: 93-110.

[19] Burr HS. Biologic organization and the cancer problem. Yale J Biol Med. 1940; 12: 277-282.

[20] Cone CD. The role of the surface electrical transmembrane potential in normal and malignant mitogenesis. Ann N Y Acad Sci. 1974; 238: 420-435.

[21] Cone CD. Unified theory on the basic mechanism of normal mitotic control and oncogenesis. J Theor Biol. 1971; 30: 151-181.

[22] Urrego D, Tomczak AP, Zahed F, Stühmer W, Pardo LA. Potassium channels in cell cycle and cell proliferation. Philos Trans R Soc B Biol Sci. 2014; 369:20130094.

[23] Prevarskaya N, Skryma R, Shuba Y. Ion channels in cancer: are cancer hallmarks oncochannelopathies? Physiol Rev. 2018; 98: 559-621.

[24] Litan A, Langhans SA. Cancer as a channelopathy: ion channels and pumps in tumor development and progression. Front Cell Neurosci. 2015; 9.

[25] Langthaler S, Rienmüller T, Scheruebel S, et al. A549 in-silico 1.0: a first computational model to simulate cell cycle dependent ion current modulation in the human lung adenocarcinoma. PLOS Comput Biol. 2021; 17:e1009091.

[26] Beck JC, Sacktor B. The sodium electrochemical potential-mediated uphill transport of D-glucose in renal brush border membrane vesicles. J Biol Chem. 1978; 253: 5531-5535.

[27] Salas PJ, López EM. Validity of the Goldman-Hodgkin-Katz equation in paracellular ionic pathways of gallbladder epithelium. Biochim Biophys Acta. 1982; 691: 178-182.

[28] Alberts B, Johnson A, Lewis J, et al. Molecular Biology of the Cell. 6th ed. Boca Raton: W.W. Norton & Company; 2017.

[29] Doyen D, Poët M, Jarretou G, et al. Intracellular pH control by membrane transport in mammalian cells. insights into the selective advantages of functional redundancy. Front Mol Biosci. 2022; 9:825028.

[30] B Alberts, editor. Molecular Biology of the Cell. 4th ed. Garland Science; 2002.

[31] Pietak A, Levin M. Bioelectrical control of positional information in development and regeneration: a review of conceptual and computational advances. Prog Biophys Mol Biol. 2018; 137: 52-68.

[32] Pietak A, Levin M. Bioelectric gene and reaction networks: computational modelling of genetic, biochemical and bioelectrical dynamics in pattern regulation. J R Soc Interface. 2017; 14:20170425.

[33] Fan JJ, Huang X. Ion channels in cancer: orchestrators of electrical signaling and cellular crosstalk. Rev Physiol Biochem Pharmacol. 2022; 183: 103-133.

[34] Di Gregorio E, Israel S, Staelens M, Tankel G, Shankar K, Tuszyński JA. The distinguishing electrical properties of cancer cells. Phys Life Rev. 2022; 43: 139-188.

[35] Bedner P, Jabs R, Steinhäuser C. Properties of human astrocytes and NG2 glia. Glia. 2020; 68: 756-767.

[36] Zhou Y, Wong C-O, Cho K, et al. Membrane potential modulates plasma membrane phospholipid dynamics and K-Ras signaling. Science. 2015; 349: 873-876.

[37] Chaffey N. Alberts, B., Johnson, A. et al. Molecular biology of the cell. Ann Bot. 2003; 91: 401-401.

[38] Pillozzi S, Arcangeli A. Physical and functional interaction between integrins and hERG1 channels in cancer cells. Adv Exp Med Biol. 2010; 674: 55-67.

[39] Gao R, Wang J, Shen Y, Lei M, Wang Z. Functional expression of voltage-gated sodium channels Nav1.5 in human breast caner cell line MDA-MB-231. J Huazhong Univ Sci Technolog Med Sci. 2009; 29: 64-67.

[40] Shan B, Dong M, Tang H, et al. Voltage-gated sodium channels were differentially expressed in human normal prostate, benign prostatic hyperplasia and prostate cancer cells. Oncol Lett. 2014; 8: 345-350.

[41] Xia J, Huang N, Huang H, et al. Voltage-gated sodium channel Na_v 1.7 promotes gastric cancer progression through MACC1-mediated upregulation of NHE1. Int J Cancer. 2016; 139: 2553-2569.

[42] Lopez-Charcas O, Poisson L, Benouna O, et al. Voltage-gated sodium Channel NaV1.5 controls NHE−1−dependent invasive properties in colon cancer cells. Cancers. 2022; 15: 46.

[43] Hengrui L. Nav channels in cancers: non-classical roles. Glob J Cancer Ther. 2020; 028-032.

[44] Besson P, Driffort V, Bon É, Gradek F, Chevalier S, Roger S. How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells? Biochim Biophys Acta BBA—Biomembr. 2015; 1848: 2493-2501.

[45] Djamgoz MBA. Electrical excitability of cancer cells—CELEX model updated. Cancer Metastasis Rev. 2024; 43: 1579-1591.

[46] Comes N, Serrano-Albarrás A, Capera J et al. Involvement of potassium channels in the progression of cancer to a more malignant phenotype. Biochim Biophys Acta BBA—Biomembr. 2015; 1848: 2477-2492.

[47] Zhu L, Yu X, Xing S, Jin F, Yang W-J. Involvement of AMP-activated protein kinase (AMPK) in regulation of cell membrane potential in a gastric cancer cell line. Sci Rep 2018; 8: 6028.

[48] Langthaler S, Zumpf C, Rienmüller T, et al. The bioelectric mechanisms of local calcium dynamics in cancer cell proliferation: an extension of the A549 in silico cell model. Front Mol Biosci. 2024; 11:1394398.

[49] Fuest S, Post C, Balbach ST, et al. Relevance of abnormal KCNN1 expression and osmotic hypersensitivity in Ewing sarcoma. Cancers. 2022; 14: 4819.

[50] Sheth M, Esfandiari L. Bioelectric dysregulation in cancer initiation, promotion, and progression. Front Oncol. 2022; 12:846917.

[51] Chernet BT, Adams DS, Lobikin M, Levin M. Use of genetically encoded, light-gated ion translocators to control tumorigenesis. Oncotarget. 2016; 7: 19575-19588.

[52] Peinado P, Stazi M, Ballabio C, et al. Intrinsic electrical activity drives small-cell lung cancer progression. Nature. 2025; 639: 765-775.

[53] Kemkar S, Tao M, Ghosh A, et al. Towards verifiable cancer digital twins: tissue level modeling protocol for precision medicine. Front Physiol. 2024; 15:1473125.

[54] Olawade DB, Oisakede EO, Bello OJ, Analikwu CC, Egbon E, Ojo A. Digital twins in oncology: from predictive modelling to personalised treatment strategies. Crit Rev Oncol Hematol. 2026; 220:105171.

[55] Carvalho J. A bioelectric model of carcinogenesis, including propagation of cell membrane depolarization and reversal therapies. Sci Rep. 2021; 11:13607.

[56] Mahapatra C, Kishore A, Gawad J, Al-Emam A, Kouzeiha RA, Rusho MA. Review of electrophysiological models to study membrane potential changes in breast cancer cell transformation and tumor progression. Front Physiol. 2025; 16:1536165.

[57] Bautista W, Lipschitz J, McKay A, Minuk GY. Cancer stem cells are depolarized relative to normal stem cells derived from human livers. Ann Hepatol. 2017; 16: 297-303.

[58] Wang W, Fan Y, Wang S, et al. Effects of voltage-gated K+ channel on cell proliferation in multiple myeloma. ScientificWorldJournal. 2014; 2014:785140.

[59] Berzingi S, Newman M, Yu H-G. Altering bioelectricity on inhibition of human breast cancer cells. Cancer Cell Int. 2016; 16: 72.

[60] Quicke P, Sun Y, Arias-Garcia M, et al. Voltage imaging reveals the dynamic electrical signatures of human breast cancer cells. Commun Biol 2022; 5: 1-14.

[61] Venkatesh HS, Morishita W, Geraghty AC, et al. Electrical and synaptic integration of glioma into neural circuits. Nature. 2019; 573: 539-545.

[62] Cüce-Aydoğmuş EM, İnhan-Garip GA. Investigation of the effects of blocking potassium channels with 4-aminopyridine on paclitaxel activity in breast cancer cell lines. Cancer Rep Hoboken, NJ; 2024; 7:e70072.

[63] Masuelli S, Real S, Campoy E, et al. When left does not seem right: epigenetic and bioelectric differences between left- and right-sided breast cancer. Mol Med Cambridge, Mass; 2022; 28: 15.

[64] Zheng B, Sumkin JH, Zuley ML, Wang X, Klym AH, Gur D. Bilateral mammographic density asymmetry and breast cancer risk: a preliminary assessment. Eur J Radiol. 2012; 81: 3222-3228.

[65] Abdou Y, Gupta M, Asaoka M, et al. Left sided breast cancer is associated with aggressive biology and worse outcomes than right sided breast cancer. Sci Rep. 2022; 12:13377.

[66] Campoy EM, Laurito SR, Branham MT, et al. Asymmetric cancer hallmarks in breast tumors on different sides of the body. PLOS ONE. 2016; 11:e0157416.

[67] Leslie TK, James AD, Zaccagna F, et al. Sodium homeostasis in the tumour microenvironment. Biochim Biophys Acta Rev Cancer. 2019; 1872:188304.

[68] Zhang P, Zhang C, Li X, et al. Immunotherapy for gastric cancer: advances and challenges. MedComm—Oncol 2024; 3:e92.

[69] Bachmann M, Pontarin G, Szabo I. The contribution of mitochondrial ion channels to cancer development and progression. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2019; 53: 63-78.

[70] Mathews J, Kuchling F, Baez-Nieto D, Diberardinis M, Pan JQ, Levin M. Ion channel drugs suppress cancer phenotype in NG108-15 and U87 cells: toward novel electroceuticals for glioblastoma. Cancers. 2022; 14: 1499.

[71] Sundelacruz S, Levin M, Kaplan DL. Membrane potential controls adipogenic and osteogenic differentiation of mesenchymal stem cells. PLoS ONE. 2008; 3:e3737.

[72] Ganapathy V, Gopal E, Miyauchi S, Prasad PD. Biological functions of SLC5A8, a candidate tumour suppressor. Biochem Soc Trans. 2005; 33: 237-240.

[73] Zhang G, Levin M. Bioelectricity is a universal multifaced signaling cue in living organisms. Mol Biol Cell. 2025; 36: pe2.

[74] Dupuy M, Gueguinou M, Postec A, et al. Chimeric protein EWS::FLI1 drives cell proliferation in Ewing Sarcoma via aberrant expression of KCNN1/SK1 and dysregulation of calcium signaling. Oncogene. 2025; 44: 79-91.

[75] Payne SL, Ram P, Srinivasan DH, Le TT, Levin M, Oudin MJ. Potassium channel-driven bioelectric signalling regulates metastasis in triple-negative breast cancer. EBioMedicine. 2022; 75:103767.

[76] McCaig CD, Rajnicek AM, Song B, Zhao M. Controlling cell behavior electrically: current views and future potential. Physiol Rev. 2005; 85: 943-978.

[77] Krishna S, Choudhury A, Keough MB, et al. Glioblastoma remodelling of human neural circuits decreases survival. Nature. 2023; 617: 599-607.

[78] Carrieri FA, Smack C, Siddiqui I, Kleinberg LR, Tran PT. Tumor treating fields: at the crossroads between physics and biology for cancer treatment. Front Oncol. 2020; 10:575992.

[79] Mrugala MM, Shi W, Iwomoto F, et al. Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011–2022. J Neurooncol. 2024; 169: 25-38.

[80] Kis-Toth K, Hajdu P, Bacskai I, et al. Voltage-gated sodium channel Nav1.7 maintains the membrane potential and regulates the activation and chemokine-induced migration of a monocyte-derived dendritic cell subset. J Immunol. 2011; 187: 1273-1280.

[81] Erdogan MA, Ugo D, Ines F. The role of ion channels in the relationship between the immune system and cancer. Curr Top Membr. 2023; 92: 151-198.

[82] Costa FP, Wiedenmann B, Schöll E, Tuszynski J. Emerging cancer therapies: targeting physiological networks and cellular bioelectrical differences with non-thermal systemic electromagnetic fields in the human body—a comprehensive review. Front Netw Physiol. 2024; 4:1483401.

[83] Lazzari-Dean JR, Gest AM, Miller EW. Optical estimation of absolute membrane potential using fluorescence lifetime imaging. eLife. 2019; 8:e44522.

[84] Arvizo RR, Miranda OR, Thompson MA, et al. Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett. 2010; 10: 2543-2548.

[85] Andres S, Pevny S, Ziegenhagen R, et al. Safety aspects of the use of quercetin as a dietary supplement. Mol Nutr Food Res. 2018; 62:1700447.

[86] Kim Y, Kim W-J, Cha E-J. Quercetin-induced growth inhibition in human bladder cancer cells is associated with an increase in Ca-activated K channels. Korean J Physiol Pharmacol Off J Korean Physiol Soc Korean Soc Pharmacol. 2011; 15: 279-283.

[87] Van Diemen HAM, Polman CH, Koetsier JC, Van Loenen AC, Nauta JJP, Bertelsmann FW. 4-Aminopyridine in patients with multiple sclerosis: dosage and serum level related to efficacy and safety. Clin Neuropharmacol. 1993; 16: 195-204.

[88] Glass DC. A review of the health effects of hydrogen sulphide exposure. Ann Occup Hyg. 1990; 34: 323-327.

[89] Mustafina AN, Yakovlev AV, Gaifullina ASh, Weiger TM, Hermann A, Sitdikova GF. Hydrogen sulfide induces hyperpolarization and decreases the exocytosis of secretory granules of rat GH3 pituitary tumor cells. Biochem Biophys Res Commun. 2015; 465: 825-831.

[90] Abduljauwad SN, Ahmed H-U-R, Moy VT. Melanoma treatment via non-specific adhesion of cancer cells using charged nano-clays in pre-clinical studies. Sci Rep. 2021; 11: 2737.

[91] Alizadeh Zeinabad H, Szegezdi E. TRAIL in the treatment of cancer: from soluble cytokine to nanosystems. Cancers. 2022; 14: 5125.

[92] Tokunaga T, Ando T, Suzuki-Karasaki M, et al. Plasma-stimulated medium kills TRAIL-resistant human malignant cells by promoting caspase-independent cell death via membrane potential and calcium dynamics modulation. Int J Oncol. 2018;52:697–708.

[93] Yu H-G, McLaughlin S, Newman M, et al. Altering calcium influx for selective destruction of breast tumor. BMC Cancer. 2017; 17: 169.

[94] Shojaee M, Feizi B, Miri R, Etemadi J, Feizi AH. Intravenous amiodarone versus digoxin in atrial fibrillation rate control: a clinical trial. Emergency Tehran, Iran; 2017; 5:e29.

[95] Gonzalez ER, Kannewurf BS, Ornato JP. Intravenous amiodarone for ventricular arrhythmias: overview and clinical use. Resuscitation. 1998; 39: 33-42.

[96] Li X, Yang F, Rubinsky B. A correlation between electric fields that target the cell membrane potential and dividing HeLa cancer cell growth inhibition. IEEE Trans Biomed Eng. 2021; 68: 1951-1956.

[97] Hagen N, Lapointe B, Ong-Lam M, et al. A multicentre open-label safety and efficacy study of tetrodotoxin for cancer pain. Curr Oncol. 2011; 18: 109-116.

[98] Loew LM. Voltage-sensitive dyes: measurement of membrane potentials induced by DC and AC electric fields. Bioelectromagnetics. 1992; 13: 179-189.

[99] Bonzanni M, Payne SL, Adelfio M, Kaplan DL, Levin M, Oudin MJ. Defined extracellular ionic solutions to study and manipulate the cellular resting membrane potential. Biol Open. 2019;bio.048553.

[100] Piatkevich KD, Jung EE, Straub C, et al. A robotic multidimensional directed evolution approach applied to fluorescent voltage reporters. Nat Chem Biol. 2018; 14: 352-360.

[101] Kofman K, Levin M. Bioelectric pharmacology of cancer: a systematic review of ion channel drugs affecting the cancer phenotype. Prog Biophys Mol Biol. 2024; 191: 25-39.

[102] Suzuki Y, Inoue T, Murai M, Suzuki-Karasaki M, Ochiai T, Ra C. Depolarization potentiates TRAIL-induced apoptosis in human melanoma cells: role for ATP-sensitive K+ channels and endoplasmic reticulum stress. Int J Oncol. 2012; 41: 465-475.

[103] Ghovanloo M-R, Abdelsayed M, Ruben PC. Effects of amiodarone and N-desethylamiodarone on cardiac voltage-gated sodium channels. Front Pharmacol. 2016; 7.

[104] Khanna C, Rosenberg M, Vail DM. A review of paclitaxel and novel formulations including those suitable for use in dogs. J Vet Intern Med. 2015; 29: 1006-1012.

[105] Sharifi-Rad J, Quispe C, Patra JK, et al., Paclitaxel: application in modern oncology and nanomedicine-based cancer therapy. Oxid Med Cell Longev. 2021; 2021:3687700.

[106] Li X, Yang F, Gao B, Yu X, Rubinsky B. A theoretical analysis of the effects of tumor-treating electric fields on single cells. Bioelectromagnetics. 2020; 41: 438-446.

[107] Neuhaus E, Zirjacks L, Ganser K, et al. Alternating electric fields (TTFields) activate Cav1.2 channels in human glioblastoma cells. Cancers. 2019; 11: 110.

[108] Persano F, Leporatti S. Nano-clays for cancer therapy: state-of-the art and future perspectives. J Pers Med. 2022; 12: 1736.

[109] Moreddu R. Nanotechnology and cancer bioelectricity: bridging the gap between biology and translational medicine. Adv Sci. 2024; 11:2304110.

[110] Beyond conceptual advances in cancer therapies. Nat Biomed Eng. 2026; 10: 407-408.

[111] Baumgartner C. The world's first digital cell twin in cancer electrophysiology: a digital revolution in cancer research? J Exp Clin Cancer Res. 2022; 41: 298, s13046-022-02507–x.

[112] Baumgartner C. Computational modeling and simulation in oncology. Clin Transl Med. 2025; 15:e70456.

[113] Sel K, Hawkins-Daarud A, Chaudhuri A, et al. Survey and perspective on verification, validation, and uncertainty quantification of digital twins for precision medicine. Npj Digit Med. 2025; 8: 40.

[114] Pammi M, Shah PS, Yang LK, Hagan J, Aghaeepour N, Neu J. Digital twins, synthetic patient data, and in-silico trials: can they empower paediatric clinical trials? Lancet Digit Health. 2025; 7:100851.

[115] Desoyer C, Ruf M, Baumgartner C. Towards a digital cancer cell twin: external pharmacological validation of a mechanistic A549 electrophysiology model. Clin Transl Discov. 2026; 6:e70112.

[116] Yang J, Griffin A, Qiang Z, Ren J. Organelle-targeted therapies: a comprehensive review on system design for enabling precision oncology. Signal Transduct Target Ther. 2022; 7: 379.

[117] Levin M. Endogenous bioelectrical networks store non-genetic patterning information during development and regeneration. J Physiol. 2014; 592: 2295-2305.

[118] Famm K, Litt B, Tracey KJ, Boyden ES, Slaoui M. Drug discovery: a jump-start for electroceuticals. Nature. 2013; 496: 159-161.

RIGHTS & PERMISSIONS

2026 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.